深度聚焦！电影《我爸没说的那件事》首映礼举行 卢靖姗惊喜助阵韩庚

电影《我爸没说的那件事》首映礼举行 卢靖姗惊喜助阵韩庚

北京 - 由著名导演曹保平执导的电影《我爸没说的那件事》今日举行首映礼，导演曹保平携主演韩庚、张国立、薛昊婧等亮相现场。青年演员卢靖姗惊喜现身，为韩庚送上祝福。

韩庚张国立同台飙戏 演绎感人父子情

电影《我爸没说的那件事》讲述了一段跨越几十年的父子亲情故事。韩庚饰演的儿子马晓远，在父亲去世后意外发现了一本日记，日记中记录了父亲不为人知的秘密。为了寻找真相，马晓远踏上了寻父之旅。

张国立饰演的父亲马建国，是一位性格倔强、不善表达感情的老工人。他一生都在为家庭默默付出，却从未得到儿子的理解。在生命的最后时刻，他终于选择将自己的秘密告诉儿子。

韩庚和张国立在片中上演了精彩的对手戏，将这对父子之间复杂而细腻的情感演绎得淋漓尽致。

卢靖姗惊喜助阵 为韩庚送上祝福

青年演员卢靖姗此次惊喜现身首映礼，为好友韩庚送上祝福。她和韩庚是多年的好友，两人曾合作过电影《战狼2》。

卢靖姗表示，自己非常期待《我爸没说的那件事》，相信这部电影一定会打动观众。她也预祝电影票房大卖。

电影将于10月31日全国上映

电影《我爸没说的那件事》将于10月31日全国上映。该片以温暖的笔触，讲述了一段感人至深的父子亲情故事，相信会引起观众的共鸣。

以下为电影《我爸没说的那件事》的相关信息：

• 片名：《我爸没说的那件事》
• 导演：曹保平
• 主演：韩庚、张国立、薛昊婧
• 上映日期：2023年10月31日

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.